NCT07599085

Brief Summary

This is an early feasibility, pre-market, prospective, interventional, single-arm, non-randomized / open-label study intended to support a future pivotal IDE study for eventual FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
12mo left

Started Aug 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 20, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2026

Expected
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

April 17, 2026

Last Update Submit

May 13, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Dialysis Cannulation Data CRF

    Percentage of attempted device cannulations that successfully result in completion of the prescribed hemodialysis treatment sessions over a 30-day period.

    30 days

  • Dialysis Cannulation Data CRF

    Proportion of subjects that, using the device, successfully complete their prescribed number of dialysis treatments over a 30-day period, excluding treatments that fail for other reasons.

    30 days

Study Arms (1)

OnePoint Dialysis Cannula

EXPERIMENTAL

Single-site vascular access device intended to be used in patients receiving hemodialysis

Device: OnePoint Dialysis Cannula

Interventions

Single-site vascular access device intended to be used in patients receiving hemodialysis

OnePoint Dialysis Cannula

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is an adult patient ≥ 18 years of age.
  • Subject with the ability to attend "in-center" hemodialysis.
  • Subject has a requirement of hemodialysis 3 times/week.
  • Subject has an AVF that was determined to be mature by standard clinical definition
  • Subject with ≥ 3 months stable in center hemodialysis with \>90 days use of an AV fistula cannulated with 2 needles with no evidence of stenosis or thrombosis.
  • Subject has an AVF that meets all of the following Rule of 5s:
  • Flow ≥ 500 mL/min
  • Diameter ≥ 5 mm
  • Depth ≤ 5 mm from the skin surface
  • Length ≥ 5 cm usable for cannulation
  • Subject does not have any established lesions or stents in the access circuit as confirmed by ultrasound.
  • Subject dialyzes at a center that can confirm 30-day data collection on cannulations and is willing to cooperate in performing real-time assessments and record keeping per Sponsor requirements, to assure subject safety requirements.

You may not qualify if:

  • Subject has an existing arteriovenous graft.
  • Subject has any active infection within the past 90 days.
  • Subject is currently receiving or planning home hemodialysis.
  • Subject has a distorted anatomy and/or local vascular injury.
  • Subject has a change in blood thinner regimen in the last 60 days.
  • Subject has any unstable medical or psychiatric conditions likely to impair their ability to participate in the study.
  • Subject has a known history of clinically significant IV drug use.
  • Subject is a pregnant or nursing woman, or anticipates pregnancy in the next 3 months.
  • Subject is enrolled in another study that could confound the results of this study, without documented pre-approval.
  • Subject has a known allergy to plastics.
  • Subject is unwilling to sign the study's consent form.
  • Subject has a life expectancy of less than 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2026

First Posted

May 20, 2026

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 1, 2027

Last Updated

May 20, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share